SeaStar Medical’s Board Gains Three New Members

Three new members have joined SeaStar Medical Holding Corporation’s Board of Directors.

Jennifer A. Baird, Bernadette N. Vincent, and John Neuman replace former directors Bruce Rodgers and Richard Russell, who did not stand for reelection at the 2024 Annual Meeting, and Andres Lobo, who retired from Dow Chemical and decided to leave the governing body as well.
 
“We are delighted to add three professionals in Jennifer, Bernadette, and John to our Board,” SeaStar Board Chairman Rick Barnett said. “Our new directors bring significant leadership, financial, and formidable industry experience that will be highly valuable as SeaStar Medical continues its transition to a commercial-stage company. We look forward to their contributions. On behalf of the board, I’d like to express our appreciation for the services provided by Andres, Bruce and Richard.”
 
Baird is the executive chair of Culturewell Co., an organization that delivers actionable insight for healthcare infection prevention through environmental sampling testing and germ risk assessments. She previously was CEO and director of the medical device software company Fifth Eye Inc. and CEO and director of the renewable energy technology company Accio Energy Inc. Prior to that, Baird co-founded and was CEO and director at the healthcare-based companies Accuri Cytometers Inc. (acquired by Becton Dickinson) and Sonetics Ultrasound Inc. She serves as a director for the non-profit Hope Clinic and advisor for the Michigan Founders Fund.

Baird earned a bachelor of arts degree in organizational psychology/leadership from the University of Michigan and an MBA from the Kellogg Graduate School of Management at Northwestern University.
 
Vincent most recently held executive roles including president, chief operating officer (COO) and chief field operations officer and was a director at Satellite Healthcare Inc., a national non-profit kidney care company. She served on the Quality, Safety & Patient Experience and the Government & Compensation Executive & Strategy committees. Prior to that, Vincent was COO for Mednax Inc., a provider of multi-specialty physician and health system services and held various leadership positions with Fresenius Medical Care North America, including group vice president and vice president of Operations. Vincent is a director for the National Kidney Foundation, California & Pacific Northwest Chapter and was founder-board member for the Laureate Academy Charter School.

Vincent earned a bachelor of science degree in nursing from Dillard University and an MBA from Pepperdine University.
 
Neuman retired from The Dow Chemical Company in 2023 after 30 years of service, most recently as vice president of Global Financial Accounting. In this position, he directed a team of approximately 350 professionals with responsibilities for financial accounting and reporting for a global network of more than 400 legal entities, including SEC filings. His tenure at Dow included finance integration and reporting responsibilities for several transactions, including the Rohm & Haas and Dow Corning acquisitions, and the Dow/DuPont merger. Prior to joining Dow, Neuman was an audit manager for Deloitte & Touche LLP.

Neuman earned a degree in accounting from Michigan State University, is a member of the Michigan State University External Advisory Board for the Department of Accounting and Information Systems, and is a certified public accountant (inactive).
 
SeaStar Medical is a commercial-stage medical technology company that is redefining the ways in which extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. The company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.